[bioundgrd] Fwd: UPDATED: MIT Biotech Group Event

[Janice Chang]

Begin forwarded message:

From: Nathan W Stebbins <nstebbin at mit.edu<mailto:nstebbin at mit.edu>>
Subject: UPDATED: MIT Biotech Group Event

**********

Please note that the event details have been updated!

The MIT Biotech Group is excited to host our first kick-off event!  Come join us and help create the vibrant community of scientists and engineers interested in the biotechnology industry. Come hear about the vision of MIT Biotech Group and find out how you can get involved! Visit biotech.mit.edu<http://biotech.mit.edu/> for more details about our organization!

Sign up soon! Space is limited as we are nearing the room’s capacity. Also, let us know if you will not be able to attend.

MIT Biotech Group Kick-off event
April 6, 2015 5pm- 7:15pm
Koch Institute auditorium (76-156)
Please RSVP http://goo.gl/T0AHc1
For questions please contact biotech at mit.edu<mailto:biotech at mit.edu>

Agenda
5:00-5:10pm- MIT Biotech Group information session
5:10-5:20pm- Vincent Hennemand- Martin-Trust Entrepreneurship Center Healthcare Sector Practice program
5:20-6:00pm- Panel discussion
6:00-7:15pm- Meet and greet with MBG members. Snack and refreshments provided!

Panelists

[VINCENT-HENNEMAND]<http://biotech.mit.edu/wp-content/uploads/2015/04/VINCENT-HENNEMAND1.jpg>

Vincent Hennemand
Vincent is a Sloan Fellow at MIT (MBA’15) and is the Healthcare Sector Practice Leader in the Martin Trust Center for Entrepreneurship. In his last role, as a Principal within Sanofi Global R&D, Vincent was responsible for developing and managing new investment opportunities for Sanofi’s Global R&D venture group. This new investment structure aimed at co-creating new ventures with external innovators and co-funding them with other strategic or financial investors. Prior to that, Vincent was the Chief of Staff to the President of Global R&D and the General Secretary for the Corporate Scientific Advisory Committee (CSAC), which investigates scientific proposals and projects of potential interest to Sanofi Global R&D. Vincent began his time at Sanofi in operational and management roles within the manufacturing division and at the corporate level, and moved to Global R&D in 2010 starting with responsibilities in project direction, strategic portfolio management and scientific intelligence.

[Geoff]<http://biotech.mit.edu/wp-content/uploads/2015/04/Geoff.jpg>

Geoffrey von Maltzahn, Ph.D. – VentureLabs Partner, Flagship Ventures
Dr. Geoffrey von Maltzahn joined Flagship in 2009 and is a VentureLabs Partner, where he focuses on inventing technologies and starting companies to address important challenges in sustainability, nutrition, and medicine. He is a founder and inventor of the platform technologies for the VentureLabs companies Seres Health, Pronutria, and Symbiota. Geoff is currently Chief Technology Officer of Symbiota and has served as the Chief Technology Officer of Seres Health, where he led the discovery of SER-109—the first clinically-validated Microbiome Therapeutic—and the generation of the company’s Microbiome Therapeutics platform. He was Vice President Discovery of Pronutria, where he led the discovery of two pharmaconutrient products in clinical testing and the development of the company’s ProNutrein platform.
Geoff is an inventor on over 100 patents and applications. He has received over 20 awards and honors for his inventions, including the Lemelson-MIT Student Prize, awarded to the most innovative student at MIT; Geoff is an author on over 20 scientific manuscripts and was awarded a Ph.D. in Biomedical Engineering and Medical Physics from MIT under the mentorship of Sangeeta N. Bhatia, MD, PhD; a M.S. in Bioengineering from the University of California, San Diego; and a S.B. in Chemical Engineering from MIT. While at MIT, Geoff was a research mentor to a 15 undergraduates and named MIT’s Most Outstanding Undergraduate Research Mentor in 2007.

[330cae4]<http://biotech.mit.edu/wp-content/uploads/2015/04/330cae4.jpg>

Raffi Mardirosian, President of Midori Renewables
Raffi Mardirosian is President at Midori, a technology startup pioneering its breakthrough Glycanogen carbohydrate synthesis platform with broad potential across Human and Animal Health. Prior to Midori, Raffi developed renewable power projects in Africa, including creating the first utility-scale solar photovoltaic power plant in East Africa which currently contributes to over 6% of Rwanda’s power, managed Business Development at Pronutria, a technology startup founded to transform global food security and nutrition, and was a consultant at McKinsey and Company, specializing in corporate healthcare, national competitiveness, sustainability and resource productivity, and global public health.
Raffi is a World Economic Forum Global Shaper, and serves as adviser to a range of organizations including Ashoka and Peace First. He is a member of the Board of Directors of eKutir, a social enterprise using a train-the-trainer model and mobile technology to transform agriculture in India. Raffi holds bachelor’s degrees from Stanford University in Economics and Public Policy, with honors in International Security and Cooperation, and conducted graduate work in International Policy Studies.
In his spare time, Raffi enjoys running, playing squash, classical piano, learning new languages, adventure travel, and taste-testing for his girlfriend’s new restaurant venture.

[IMG_4480]<http://biotech.mit.edu/wp-content/uploads/2015/04/IMG_4480.jpg>

Armon Sharei, Ph.D.-  CEO and Co-founder of SQZ Biotech
Dr. Armon Sharei received his B.S. from Stanford University and his Ph.D. in Chemical Engineering from MIT, under the guidance of Prof. Klavs Jensen and Prof. Robert Langer. He was a national finalist for the NIH Director’s Early Independence Award in 2013, and was a Ragon Institute Fellow at Harvard Medical School under the mentorship of Prof. Ulrich von Andrian and Prof. Darrell Irvine. He is co-founder and CEO of SQZ Biotechnologies, and led the development of the CellSqueeze platform which has demonstrated enabling potential in applications ranging from cell reprogramming to immunotherapies. This work has been highlighted by many sources including Nature and Scientific American, and was recently named one of the top 10 world changing ideas of 2014 by Scientific American. Dr. Sharei was selected as one of the 30 Under 30 by Forbes in the Healthcare category in 2015, and is a co-author on 11 peer-reviewed publications and an inventor on 6 patents.

This event is sponsored by the GSC start-up fund & the Martin-Trust Entrepreneurship Center

[GSC-Sponsor-Logo-White][logo-trustCenter]


-------------- next part --------------
An HTML attachment was scrubbed...
URL: http://mailman.mit.edu/pipermail/bioundgrd/attachments/20150403/03aeae63/attachment-0001.htm